GC Biopharma to develop mRNA flu vaccine with Canadian pharma

The company aims to enter phase 1 clinical trials next year, using Acuitas Therapeutics’ lipid nano particle technology

GC Biopharma to develop mRNA flu vaccine with Canadian pharma
Jae-Young Han 1
2023-03-09 17:58:39 jyhan@hankyung.com
Bio & Pharma

South Korea's GC Biopharma Corp. announced on Thursday that it will start developing a flu vaccine based on messenger ribonucleic acid (mRNA).

The drug maker said it has exercised an option contract with Acuitas Therapeutics, a Canadian pharma that specializes in lipid nano particle (LNP) delivery systems for mRNA-based drugs. 

Two companies signed an option agreement for development of LNP technology in April last year. GC Biopharma recently exercised an option of non-exclusive licensing agreement. 

LNP is a method of encapsulating and transporting mRNA molecules to the target cells in the body. "Acuitas’ LNP technology was also used in Pfizer’s COVID-19 vaccine," a GC Biopharma source said. 

GC Biopharma aims to enter phase 1 clinical trials next year by leveraging its existing expertise in flu vaccines and Acuitas’ technology. It also decided to invest in pilot production facilities for mRNA vaccine at its current flu vaccine plant in Hwasun, South Jeolla Province.

"We will accelerate the development of innovative new drugs in the fields of vaccines and rare diseases through mRNA platform technology and secure next-generation growth engines," Eun-chul Huh, CEO of GC Biopharma said. 

Write to Jae-Young Han at jyhan@hankyung.com

GC Biopharma introduces candidates for treating blood coagulation disease

GC Biopharma introduces candidates for treating blood coagulation disease

Nassim Usman, CEO of Catalyst Biosciences(left) and Huh Eun-chul, CEO of GC Biopharma South Korea's GC Biopharma Corp. announced on Tuesday that it had entered into an agreement to transfer assets with Catalyst Biosciences, a US-based drug development firm, in order to introduce drug candidates

GC Biopharma gets WHO pre-qualification approval for chickenpox vaccine

GC Biopharma gets WHO pre-qualification approval for chickenpox vaccine

South Korea's GC Biopharma Corp. is set to regain the No. 1 spot in global production of chickenpox vaccines after earning qualification to enter the World Health Organization (WHO) procurement market with Barycela following its export hit Suduvax. This breakthrough is expected to heat up glob

GC Biopharma's Sanfilippo treatment eligible for FDA priority review

GC Biopharma's Sanfilippo treatment eligible for FDA priority review

GC Biopharma headquarters  GC Biopharma Corp. said on Wednesday that its Sanfilippo type A treatment, which is under joint development with Novel Pharma, a bio-venture specializing in orphan drugs, has received rare pediatric disease designation (RPDD) from the US Food and Drug Administrat

GC Biopharma, Sanofi to jointly market Plavix

GC Biopharma, Sanofi to jointly market Plavix

Plavix GC Biopharma Co. (formerly Green Cross Corp.) said on Monday it has entered into a joint sales partnership with Sanofi-Aventis Korea, the South Korean subsidiary of multinational pharmaceuticals company Sanofi, for Plavix 75 mg, an antiplatelet medication.The agreement calls for GC Bioph

GC Biopharma's Ochang facility gets WHO PQ certification

GC Biopharma's Ochang facility gets WHO PQ certification

GC Biopharma GC Biopharma Co.'s production facility in Ochang (North Chungcheong Province) secured a pre-qualification (PQ) certification from the World Health Organization (WHO).According to the company formerly known as GC Green Cross on Thursday, the 'integrated finished product facility' in
(* comment hide *}